recombinant IL-12 (Wistar Institute)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namerecombinant IL-12 (Wistar Institute)
Drug Alias Namerecombinant interleukin-12 (Wistar Institute)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionInterleukin-12 receptor stimulants
TargetsInterleukin-12 receptor
Therapy Area/IndicationsInflammationNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesThe Wistar Institute Of Anatomy And Biology
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe Wistar Institute Of Anatomy And Biology
Active IndicationsN/A
Inactive IndicationsInflammationNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A